Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 81 of 2812 for:    Neoplasms, Germ Cell and Embryonal | Neuroendocrine Tumors

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01364415
Recruitment Status : Completed
First Posted : June 2, 2011
Last Update Posted : June 28, 2016
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016